Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118278496> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W3118278496 endingPage "S788" @default.
- W3118278496 startingPage "S788" @default.
- W3118278496 abstract "Abstract Background Ceftolozane/tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor approved by FDA and EMA for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Elevated antimicrobial resistance rates have been reported among pathogens collected in ICUs. Using isolates collected in Asia/Pacific as part of the global SMART surveillance program, we evaluated the activity of C/T and comparators against P. aeruginosa from patients with respiratory tract infections (RTI) in ICU and non-ICU wards. Methods In 2016-2018, 55 clinical laboratories in 11 Asia/Pacific countries collected 2530 P. aeruginosa isolates from RTI. MICs were determined using CLSI broth microdilution and interpreted with CLSI breakpoints. C/T-nonsusceptible isolates (except those from India) were screened by PCR and sequencing for genes encoding β-lactamases. Results Susceptibility to C/T in Asia/Pacific was 85.3% in ICUs and 92.2% in non-ICUs, 15-23 percentage points and 13-19 percentage points, respectively, higher than to meropenem, cefepime, and piperacillin-tazobactam. C/T maintained activity against 58.8% and 69.4% of meropenem-nonsusceptible isolates from ICU (n=294) and non-ICU patients (n=346), respectively. Acquired β-lactamases were detected in 64% of C/T-nonsusceptible isolates from ICUs (n=90; 54% MBL-positive, 1% GES carbapenemase-positive, 9% ESBL-positive) and in 47% of C/T-NS isolates from non-ICUs (n=86; 33% MBL-positive, 6% GES-carbapenemase-positive, 8% ESBL-positive). The table presents country-level rates of C/T-susceptible and carbapenemase-positive P. aeruginosa for countries with n >20 in both ICU and non-ICU subsets. Table Conclusion In Asia/Pacific overall, C/T maintained susceptibility rates >85% in both ICU and non-ICU wards against P. aeruginosa isolates from RTI, with rates >91% in most countries. Susceptibility was lower in countries with higher rates of carbapenemase-positive P. aeruginosa. C/T could provide an important treatment option for RTI infections caused by P. aeruginosa in the Asia/Pacific region. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Wei-Ting Chen, MD, Merck, Sharp & Dohme, Taiwan (Employee) Yivonne Khoo, PhD, Merck, Sharp & Dohme, Malaysia (Employee) Kanchan Balwani, MBBS, MS, Merck, Sharp & Dohme, Hong Kong (Employee) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
- W3118278496 created "2021-01-18" @default.
- W3118278496 creator A5008370890 @default.
- W3118278496 creator A5017159626 @default.
- W3118278496 creator A5038009031 @default.
- W3118278496 creator A5042149117 @default.
- W3118278496 creator A5042818728 @default.
- W3118278496 creator A5048325629 @default.
- W3118278496 creator A5066677972 @default.
- W3118278496 creator A5089366807 @default.
- W3118278496 date "2020-10-01" @default.
- W3118278496 modified "2023-10-15" @default.
- W3118278496 title "1581. In Vitro Activity of Ceftolozane/Tazobactam against Pseudomonas aeruginosa from ICU and Non-ICU Patients with Respiratory Tract Infections in the Asia/Pacific region – SMART 2016-2018" @default.
- W3118278496 doi "https://doi.org/10.1093/ofid/ofaa439.1761" @default.
- W3118278496 hasPublicationYear "2020" @default.
- W3118278496 type Work @default.
- W3118278496 sameAs 3118278496 @default.
- W3118278496 citedByCount "0" @default.
- W3118278496 crossrefType "journal-article" @default.
- W3118278496 hasAuthorship W3118278496A5008370890 @default.
- W3118278496 hasAuthorship W3118278496A5017159626 @default.
- W3118278496 hasAuthorship W3118278496A5038009031 @default.
- W3118278496 hasAuthorship W3118278496A5042149117 @default.
- W3118278496 hasAuthorship W3118278496A5042818728 @default.
- W3118278496 hasAuthorship W3118278496A5048325629 @default.
- W3118278496 hasAuthorship W3118278496A5066677972 @default.
- W3118278496 hasAuthorship W3118278496A5089366807 @default.
- W3118278496 hasBestOaLocation W31182784961 @default.
- W3118278496 hasConcept C126322002 @default.
- W3118278496 hasConcept C176947019 @default.
- W3118278496 hasConcept C177713679 @default.
- W3118278496 hasConcept C2777050379 @default.
- W3118278496 hasConcept C2777184939 @default.
- W3118278496 hasConcept C2777637488 @default.
- W3118278496 hasConcept C2777858937 @default.
- W3118278496 hasConcept C2777914695 @default.
- W3118278496 hasConcept C2778193466 @default.
- W3118278496 hasConcept C2778266534 @default.
- W3118278496 hasConcept C2779375183 @default.
- W3118278496 hasConcept C2779631663 @default.
- W3118278496 hasConcept C2780950330 @default.
- W3118278496 hasConcept C2987404301 @default.
- W3118278496 hasConcept C4937899 @default.
- W3118278496 hasConcept C501593827 @default.
- W3118278496 hasConcept C523546767 @default.
- W3118278496 hasConcept C54355233 @default.
- W3118278496 hasConcept C71924100 @default.
- W3118278496 hasConcept C86803240 @default.
- W3118278496 hasConcept C89423630 @default.
- W3118278496 hasConcept C94665300 @default.
- W3118278496 hasConceptScore W3118278496C126322002 @default.
- W3118278496 hasConceptScore W3118278496C176947019 @default.
- W3118278496 hasConceptScore W3118278496C177713679 @default.
- W3118278496 hasConceptScore W3118278496C2777050379 @default.
- W3118278496 hasConceptScore W3118278496C2777184939 @default.
- W3118278496 hasConceptScore W3118278496C2777637488 @default.
- W3118278496 hasConceptScore W3118278496C2777858937 @default.
- W3118278496 hasConceptScore W3118278496C2777914695 @default.
- W3118278496 hasConceptScore W3118278496C2778193466 @default.
- W3118278496 hasConceptScore W3118278496C2778266534 @default.
- W3118278496 hasConceptScore W3118278496C2779375183 @default.
- W3118278496 hasConceptScore W3118278496C2779631663 @default.
- W3118278496 hasConceptScore W3118278496C2780950330 @default.
- W3118278496 hasConceptScore W3118278496C2987404301 @default.
- W3118278496 hasConceptScore W3118278496C4937899 @default.
- W3118278496 hasConceptScore W3118278496C501593827 @default.
- W3118278496 hasConceptScore W3118278496C523546767 @default.
- W3118278496 hasConceptScore W3118278496C54355233 @default.
- W3118278496 hasConceptScore W3118278496C71924100 @default.
- W3118278496 hasConceptScore W3118278496C86803240 @default.
- W3118278496 hasConceptScore W3118278496C89423630 @default.
- W3118278496 hasConceptScore W3118278496C94665300 @default.
- W3118278496 hasIssue "Supplement_1" @default.
- W3118278496 hasLocation W31182784961 @default.
- W3118278496 hasLocation W31182784962 @default.
- W3118278496 hasLocation W31182784963 @default.
- W3118278496 hasOpenAccess W3118278496 @default.
- W3118278496 hasPrimaryLocation W31182784961 @default.
- W3118278496 hasRelatedWork W2013041033 @default.
- W3118278496 hasRelatedWork W2367815082 @default.
- W3118278496 hasRelatedWork W2582089891 @default.
- W3118278496 hasRelatedWork W2782181787 @default.
- W3118278496 hasRelatedWork W2971381917 @default.
- W3118278496 hasRelatedWork W3118278496 @default.
- W3118278496 hasRelatedWork W3119078717 @default.
- W3118278496 hasRelatedWork W3202593657 @default.
- W3118278496 hasRelatedWork W4200090408 @default.
- W3118278496 hasRelatedWork W4205758426 @default.
- W3118278496 hasVolume "7" @default.
- W3118278496 isParatext "false" @default.
- W3118278496 isRetracted "false" @default.
- W3118278496 magId "3118278496" @default.
- W3118278496 workType "article" @default.